Frontiers in endocrinology · 2025
Genetic/epigenetic RNA dysregulation in type 2 diabetes mellitus complicated with ischemic heart disease.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sedkey Eslam S, Matboli Marwa, Seadawy Mohamed G, Hegazy Marwa G A
Аннотация
INTRODUCTION: Diabetes mellitus is a major independent determinant of cardiovascular morbidity. Therefore, we evaluated whether a molecular RNA panel comprising FZD5 and GTF2I could facilitate the early detection and discrimination of ischemic heart disease in individuals with type 2 diabetes mellitus.
METHODS: We implemented a two-stage bioinformatics workflow to identify and validate two mRNA candidates associated with T2DM and IHD. Subsequently, we delineated non-coding RNAs linked to these transcripts and the pathways potentially implicated in T2DM complicated by IHD. Finally, we conducted a pilot case-control study and quantified the panel members by RT-qPCR in 56 patients with T2DM, 25 with IHD, 26 with combined T2DM+IHD, and 60 matched controls.
RESULTS: Differential expression analysis showed upregulation of hsa-miR-1976, FZD5, and GTF2I, accompanied by downregulation of LINC02210 in the T2DM+IHD group versus controls. The RNA panel achieved high discriminatory performance (AUC = 0.94) between T2DM+IHD and controls, highlighting its potential as a discriminatory tool.
DISCUSSION: this study identified clinically relevant non-coding RNA-based angiogenesis panel (FZD5, GTF2I mRNAs, hsa-miR-1976 and LINC02210 lncRNA) as a biomarker signature associated with type 2 diabetes mellitus complicated by ischemic heart disease.
METHODS: We implemented a two-stage bioinformatics workflow to identify and validate two mRNA candidates associated with T2DM and IHD. Subsequently, we delineated non-coding RNAs linked to these transcripts and the pathways potentially implicated in T2DM complicated by IHD. Finally, we conducted a pilot case-control study and quantified the panel members by RT-qPCR in 56 patients with T2DM, 25 with IHD, 26 with combined T2DM+IHD, and 60 matched controls.
RESULTS: Differential expression analysis showed upregulation of hsa-miR-1976, FZD5, and GTF2I, accompanied by downregulation of LINC02210 in the T2DM+IHD group versus controls. The RNA panel achieved high discriminatory performance (AUC = 0.94) between T2DM+IHD and controls, highlighting its potential as a discriminatory tool.
DISCUSSION: this study identified clinically relevant non-coding RNA-based angiogenesis panel (FZD5, GTF2I mRNAs, hsa-miR-1976 and LINC02210 lncRNA) as a biomarker signature associated with type 2 diabetes mellitus complicated by ischemic heart disease.